trending Market Intelligence /marketintelligence/en/news-insights/trending/ILP5a7ctyivtKZc9NALKYQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eisai initiates late-stage study of Alzheimer's drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eisai initiates late-stage study of Alzheimer's drug

SNL Image

Shortly after discontinuing two late-stage trials of Alzheimer's disease drug aducanumab, Eisai Co. Ltd. said it started a global late-stage study of another drug for the disease.

The Japanese drugmaker said it initiated a phase 3 study of BAN2401 in patients with early Alzheimer's disease.

The trial, dubbed Clarity AD or Study 301, involves 1,566 patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia with confirmed amyloid pathology in the brain.

Alzheimer's disease is the most common cause of dementia. The disorder is characterized by the progressive loss of memory and other mental functions.

Clarity AD's main goal is the change from baseline in the cognitive and functional performance of the patients, including memory, orientation, judgement and problem solving, community affairs, as well as home and hobbies, and personal care, after 18 months of treatment.

The Tokyo-based pharmaceutical company, which is co-developing the investigational drug with Biogen Inc., will use the study's results to support a regulatory filing for the drug. BAN2401 previously failed to meet the main goals of a mid-stage trial known as Study 201 in December 2017.

Eisai and Biogen discontinued two late-stage trials evaluating aducanumab, another Alzheimer's disease drug, after analysis showed the studies were unlikely to meet their main goals.